• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS; ILIAC COVERED STENT, ARTERIAL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS; ILIAC COVERED STENT, ARTERIAL Back to Search Results
Catalog Number BXB057902A
Medical Device Problem Code Patient-Device Incompatibility (2682)
Health Effect - Clinical Codes Aneurysm (1708); Vascular Dissection (3160)
Date of Event 07/10/2025
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
C.1.Cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Event or Problem Description
The following information was reported to gore on (b)(6) 2025, from the imedidata study database: on (b)(6) 2025, the patient underwent endovascular treatment of a type iii thoracoabdominal aortic aneurysm.The patient was treated with a gore® excluder® thoracoabdominal branch endoprosthesis (tambe) aortic component and gore® viabahn® vbx balloon expandable endoprosthesis (vbx) devices.It was reported that, after deployment of the vbx devices in the left renal artery, a renal artery aneurysm with focal dissection was observed.The dissection was treated via an unplanned procedure.The left renal artery was embolized with a plug.The patient was discharged to a skilled nursing facility on (b)(6) 2025.
 
Additional Manufacturer Narrative
H6: investigation findings for analysis of production records: code c21 updated to code c19.H6: investigation findings for analysis of production records: code c19: the review of the manufacturing paperwork verified that the lots involved in this event met all pre-release specifications.H6: investigation conclusions: code d16 updated to code d15.H6: investigation conclusions: code d15: there is insufficient information available for gore to reasonably draw conclusions related to aspects of the event, therefore conclusion code ¿d15: cause not established¿ is being used.Insufficient information may include limited or missing relevant medical records, involvement of multiple implanted devices (including non-gore devices) in the field of treatment, patient non-compliance, and/or a general lack of available detail or specificity related to an adverse event and/or device.H6: investigation conclusions: code d12 added.According to the gore® viabahn® vbx balloon expandable endoprosthesis instructions for use (ifu), possible adverse events and complications that may occur with the use of this device, or in any endovascular procedure, and require intervention include, but are not limited to, trauma to the vessel wall (including rupture or dissection).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS
Common Device Name
ILIAC COVERED STENT, ARTERIAL
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL ECHO RIDGE B/P
3250 w. kiltie lane
flagstaff AZ 86005
Manufacturer Contact
jenna lopez
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key22908470
Report Number2017233-2025-06534
Device Sequence Number13033885
Product Code PRL
UDI-Device Identifier00733132658367
UDI-Public(01)00733132658367(17)270922
Combination Product (Y/N)Y
Initial Reporter StateWI
Initial Reporter CountryUS
PMA/510(K) Number
P160021
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2025
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Study
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 09/24/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Catalogue NumberBXB057902A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 07/28/2025
Supplement Date Received by Manufacturer09/24/2025
Initial Report FDA Received Date08/27/2025
Supplement Report FDA Received Date09/24/2025
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured09/23/2024
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Other; Required Intervention;
Patient Age75 YR
Patient SexFemale
Patient Weight86 KG
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-